AC
ANRO icon

Armistice Capital’s Alto Neuroscience ANRO Stock Holding History

Armistice Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.5M Sell
912,000
-624,000
-41% -$11.6M 0.36% 57
2025
Q4 		$27.3M Sell
1,536,000
-100,000
-6% -$1.26M 0.33% 48
2025
Q3 		$6.58M Buy
1,636,000
+12,000
+0.7% +$39.8K 0.1% 100
2025
Q2 		$3.57M Buy
1,624,000
+24,000
+2% +$57.1K 0.06% 111
2025
Q1 		$3.46M Buy
1,600,000
+950,000
+146% +$3.4M 0.05% 130
2024
Q4 		$2.75M Buy
+650,000
New +$4.06M 0.04% 138

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Armistice Capital's ANRO Position: Q1 2026 in Review

Armistice Capital reduced its Alto Neuroscience (ANRO) stake by 41% in Q1 2026, selling an estimated $11.6M and leaving 912,000 shares worth $20.5M. The position accounts for 0.36% of the portfolio, ranked #57.

Armistice Capital first reported a position in ANRO in Q4 2024 and has held it in 6 quarters since. The position peaked at $27.3M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Armistice Capital held 912,000 shares of Alto Neuroscience worth $20.5M as of Q1 2026.
  • Armistice Capital sold 624,000 Alto Neuroscience shares in Q1 2026, an estimated $11.6M.
  • Alto Neuroscience made up 0.36% of Armistice Capital's portfolio in Q1 2026, its #57 holding.
  • Armistice Capital first reported a position in Alto Neuroscience in Q4 2024 and has held it in 6 quarters since.
  • Armistice Capital's Alto Neuroscience position peaked at $27.3M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.